First patient enrolled in Agni-01 expansion

Postmenopausal study highlights oral anabolic potential

Decision expands options for eligible patients

Study evaluates tri‑specific T cell engager LBL‑051

Designation supports accelerated access for investigational antibody

EC expands use to protect youngest children

New therapy aims to tackle antibiotic resistance

Regulators assess PB016 vedolizumab biosimilar applications

Researchers highlight minimally invasive monitoring potential

First-in-human evaluation of infinitopes’ therapeutic platform